1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2009. www.goldcopd.org.
2. Anthonisen NR, Wright EC, Hodgkin JE. The IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14–20.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of COPD. Eur Respir J 2004; 23: 932–46.
4. Agusti AGN, Noguera A, Sauleda J et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347–60.
5. Casanova C, Cote C, de Torres JP et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 591–7.
6. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791–7.
7. Maltais F, LeBlanc P, Jobin J et al. Intensity of training and physiologic adaptation in patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 555–61.
8. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–40.
9. Reilly JJ. COPD and Declining FEV1 – Time to Divide and Conquer? N Engl J Med 2008; 359: 1616–18.
10. Rice JP, Saccone NL, Rasmussen E. Definition of the phenotype. Adv Genet 2001; 42: 69–76.
11. Han MK, Agusti A, Calverley PM et al. COPD phenotypes: The future of COPD. Am J Respir Crit Care Med 2010; 182: 598–604.
12. Dornhorst AC. Respiratory insufficiency. Lancet 1955; 268: 1185–7.
13. Burrows B, Fletcher CM, Heard BE et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966; 87: 830–5.
14. Diaz O, Villafranca C, Ghezzo H et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without expiratory flow limitation at rest. Eur Respir J 2000; 16: 269–75.
15. Garcia-Aymerich J, Agusti А, Barberа JA et al. Phenotypic Heterogeneity of Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2009; 45: 133–42.
16. Lee J-H, Lee YK, Kim E-K et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010; 104: 542-9.
17. Gelb AF, Taylor CF, Cassino C et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm Pharmacol Ther 2009; 22: 237–42.
18. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
19. Pinto-Plata VM, Celli-Cruz RA, Vassaux C et al. Differences in cardiopulmonary exercise test results by American Thoracic Society/European Respiratory SocietyGlobal Initiative for Chronic Obstructive Lung Disease stage categories and gender. Chest 2007; 132: 1204–11.
20. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006; 15: 346–53.
21. Decramer M, Celli B, Kesten S et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespeci_ed subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–8.
22. Pena VS, Miravitlles M, Gabriel R et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981–9.
23. Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397–412.
24. Жестков А.В., Косарев В.В., Бабанов С.А. Хроническая обструктивная болезнь легких у жителей крупного промышленного центра: эпидемиология и факторы риска. Пульмонология 2009; 6: 53-7.
25. Troosters T, Celli B, Lystig T et al. Tiotropium as a First Maintenance Drug in COPD: Secondary Analysis of the UPLIFT trial. ERJ Express. Published on February 25, 2010 as doi: 10.1183/09031936.00127809
26. Mannino DM, Homa DM, Akinbami LJ et al. Chronic obstructive pulmonary disease surveillance – United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1–16.
27. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645–8.
28. Morice AH, Celli B, Kesten S et al. COPD patients under 50 years of age: 4-year follow-up in the UPLIFT trial. Abstract presented at European Respiratory Society Annual Congress, Vienna, Austria, September 2009. [P3801].
29. Moita J, Barbara C, Cardoso J et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008; 21: 146–51.
30. Rennard SI, Serby CW, Ghafouri M et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. Chest 1996; 110: 62–70.
31. Tashkin DP, Celli B, Kesten S et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010; 35: 287–94.